Treatment for Ringworm
For tinea corporis, cruris, and pedis, use topical terbinafine or butenafine cream for 1-2 weeks as first-line therapy; reserve oral antifungals for extensive, severe, or treatment-resistant cases. 1
First-Line Treatment: Topical Antifungals
For localized ringworm infections of the body, groin, and feet, topical therapy is the standard approach:
- Terbinafine cream is highly effective, showing significantly higher clinical cure rates compared to placebo (RR 4.51, NNT 3) 2
- Naftifine 1% also demonstrates strong efficacy with mycological cure rates favoring it over placebo (RR 2.38, NNT 3) 2
- Azoles (clotrimazole, miconazole, ketoconazole) are effective alternatives, with clotrimazole showing mycological cure rates of RR 2.87 compared to placebo 2
Apply topical agents once or twice daily for 1-4 weeks depending on the specific agent. Terbinafine and naftifine offer the advantage of shorter treatment duration (1-2 weeks) compared to azoles (2-4 weeks) 1, 2.
When to Use Oral Antifungals
Systemic therapy is indicated when the infection is:
- Multiple or extensive lesions
- Deep or severe (including moccasin-type tinea pedis)
- Recurrent or chronic
- Unresponsive to topical treatment
- In immunocompromised patients 3, 1
Oral terbinafine is first-line for systemic therapy due to its tolerability, high cure rate, and low cost 1.
Critical Pitfalls to Avoid
Do NOT use combination antifungal-corticosteroid products. While these combinations show slightly higher clinical cure rates at end of treatment (RR 0.67 for azoles alone vs combination), they provide no difference in mycological cure 2. Current data shows 7-10% of patients are inappropriately prescribed these combinations 4. The steroid component can mask symptoms while allowing fungal proliferation, leading to more extensive disease.
Diagnostic Confirmation
While diagnosis is often clinical, confirm with KOH preparation or culture when:
- Diagnosis is uncertain
- Disease is extensive or severe
- Treatment has failed
- Patient is immunocompromised 1
Only 10% of patients currently receive diagnostic testing 4, but this is increasingly important given emerging antifungal resistance, particularly with Trichophyton indotineae (formerly T. mentagrophytes genotype VIII), which shows terbinafine resistance 5.
Emerging Resistance Concerns
Be aware that difficult-to-treat, antifungal-resistant dermatophyte infections are increasing globally. T. indotineae presents as inflammatory, extensive infections prone to persistence and relapse despite standard therapy 5. If treatment fails after appropriate topical or oral therapy, consider:
- Fungal culture with susceptibility testing
- Alternative oral agents (itraconazole, fluconazole)
- Longer treatment duration
Treatment Duration and Follow-up
- Topical therapy: 1-2 weeks for allylamines (terbinafine, naftifine); 2-4 weeks for azoles
- Oral therapy: Typically 2-4 weeks, but may require longer courses for resistant cases
- Adverse effects are generally mild (irritation, burning) and infrequent across all topical agents 2
The evidence base consists primarily of studies rated as low to very low quality, with many over 20 years old 2. However, the consistent effectiveness of terbinafine and naftifine across multiple studies supports their use as preferred first-line topical agents.